Major drugmakers and top agencies alike earned their flowers at the annual Fierce Pharma Marketing Awards gala in ...

GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.  | GSK is ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid what a spokesperson said is ...

GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.

GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3 trial, painting ...

GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start ...

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

GSK is paying $110 million upfront to Hutchmed in a deal worth up to $1.295 billion. Now in its fifth year, the MM+M Media Summit 2026 brings together trailblazers from across health media and pharma ...

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

(Alliance News) - GSK PLC on Tuesday said it has agreed to buy "a potential best-in-class" T cell-engager aimed at treating multiple myeloma from China-based clinical-stage biotechnology company ...